BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MWG and Operon Biotechnologies, Inc. Are Joining Forces


12/4/2007 8:17:53 AM

EBERSBERG, Germany and HUNTSVILLE, Ala., Dec. 3 /PRNewswire/ -- Operon Biotechnologies, Eurofins MWG and Eurofins Medigenomix - all part of the Eurofins Genomics network - announced today that they have agreed to work together in order to create a new worldwide leader in the competitive custom oligonucleotide market. With about $US 50M in revenue and state of the art high-throughput production facilities in all major markets (North America, Europe and Asia) the new network of companies intends to offer the market an unrivalled level of performance and efficiency in the custom DNA service area.

"Over the past 10 years overcapacity in the market has put a lot of pressure on all custom oligonucleotide synthesis service suppliers. Prices have decreased to a level where very few companies are able to keep up with the level of investment and innovation needed to meet the market demand for lower cost and higher quality of products and services. By joining the expertise, the resources and the experience of two major players in the field, we are convinced that we can take the next quantum leap which our customers expect from us," says Patrick Weiss, Managing Director of Operon Biotechnologies, Inc. and future CEO of Eurofins Genomics.

"Enabling Operon and Eurofins Genomics subsidiaries Eurofins MWG and Eurofins Medigenomix to work together strengthens our position in the custom oligonucleotides business and creates new opportunities for further development of additional services in the genomic services field. This will give the market, and in particular Eurofins customers in Biotechnology, Pharmaceutical, Food and Environment industries access to improved DNA services and innovative DNA-based testing," says Bruno Poddevin, Head of the Eurofins Genomics Services Cluster.

For further information please visit our websites www.mwgdna.com www.operon.com

CONTACT: Dr. Jutta Huber of MWG-Biotech AG, +08092-8289-930,
jhuber@mwgdna.com; or Patrick Weiss of Operon Biotechnologies, Inc.,
+1-256-704-8151, angela.hardin@operon.com

Web site: http://www.operon.com/
http://www.mwgdna.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES